Occupancy
68%
+?pp YoY
Group occupancy was 68%, with headroom to reach 70-72% next year.
APOLLOHOSP
Healthcare
14 Nov 2023
Apollohosp Ltd — Q2 FY24
Apollo Hospitals reported a robust Q2 FY24 with consolidated revenue of INR 4,847 crore (+14% YoY) and EBITDA of INR 628 crore (+11% YoY).
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Apollo Hospitals reported a robust Q2 FY24 with consolidated revenue of INR 4,847 crore (+14% YoY) and EBITDA of INR 628 crore (+11% YoY). Healthcare services revenue grew 12% to INR 2,547 crore, driven by 18% growth in insurance revenues (now 43% of IP revenue) and 20% growth in international patients. Occupancy stood at 68%, with ARPOB up 14% to INR 57,379. The pharmacy business grew 21% YoY, and Apollo 24|7 added 2 million new users, targeting operational breakeven by Q4 FY24. Management guided for 200 bps margin expansion in hospitals and 6%+ EBITDA margin for pharmacy. Key risks include delayed ramp-up of new bed additions and competitive intensity in metro markets.
अपोलो हॉस्पिटल्स ने दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 4,847 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। कमाई में से मुनाफा (EBITDA) 628 करोड़ रुपये रहा, जो 11% बढ़ा है। अस्पताल सेवाओं से कमाई 12% बढ़कर 2,547 करोड़ रुपये हुई। बीमा से कमाई 18% और विदेशी मरीजों से 20% बढ़ी। अस्पतालों में 68% बिस्तर भरे रहे। दवा का कारोबार 21% बढ़ा। Apollo 24|7 ने 20 लाख नए ग्राहक जोड़े। कंपनी अस्पतालों में मुनाफा बढ़ाने और दवा कारोबार में सुधार की योजना बना रही है। जोखिम: नए बिस्तर जोड़ने में देरी और बड़े शहरों में प्रतिस्पर्धा।
Key Numbers
ARPOB
INR 57,379
+14% YoY
Average revenue per occupied bed increased due to better payer mix and case mix.
Insurance Revenue Share
43%
+?pp YoY
Insurance now contributes 43% of inpatient revenue, up from ~30% pre-COVID.
Apollo 24|7 Users
29M
+2M QoQ
Digital platform added 2 million new users in Q2, reaching 29 million total.
What Changed vs Last Quarter
NEW
Hospital EBITDA margin expansion of 200 bps
Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement.
NEW
Addition of 2,300 beds over three years at INR 3,400 crore
Apollo plans to add 2,300 beds across eight locations over the next three financial years, with a capital outlay of INR 3,400 crore.
UPDATED
Pharmacy omni-channel revenue of INR 10,000 crore and 6%+ EBITDA margin
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
UPDATED
Apollo 24|7 operational breakeven in Q4 FY24
The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24.
DROPPED
Occupancy target of 70% without additional CapEx
Management expects to reach 70% occupancy over time without requiring significant capital expenditure, leveraging existing capacity.
DROPPED
Discount rationalization to 13-14% range for online pharmacy
Management guided that online pharmacy discounts will remain in the 13-14% range for the rest of FY24, with offline discounts at 12-12.5%.
NEW RISK
Delayed monsoon impacted medical admissions in South India
Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.
NEW RISK
New hospital ramp-up may pressure near-term margins
Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.
NEW RISK
Competitive intensity in metro markets
Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage.
RISK GONE
Occupancy ramp-up slower than expected
Overall occupancy at 62% remains below the 70% target, with new hospitals at 60% and some regions like Tamil Nadu seeing muted volumes due to seasonal factors.
RISK GONE
Margin pressure from new store additions and clinical investments
Combined pharmacy EBITDA margins are under pressure due to 20% of stores yet to reach breakeven, and new hospitals face margin drag from doctor hiring and marketing costs.
RISK GONE
Apollo 24|7 GMV growth may be impacted by discount reduction
The decision to reduce discounts and filter low-value orders led to a sequential decline in pharmacy GMV, and achieving the INR 3,000 crore GMV target may be challenging.
RISK GONE
Indraprastha Medical lease renewal uncertainty
Management deferred providing an update on the lease renewal for Indraprastha Medical, which could impact future operations and expansion plans.
Management Guidance
Hospital EBITDA margin expansion of 200 bps
Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement.
Management guidance marginsPharmacy omni-channel revenue of INR 10,000 crore and 6%+ EBITDA margin
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
Management guidance revenueApollo 24|7 operational breakeven in Q4 FY24
The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24.
Management guidance growthAddition of 2,300 beds over three years at INR 3,400 crore
Apollo plans to add 2,300 beds across eight locations over the next three financial years, with a capital outlay of INR 3,400 crore.
Management guidance capexKey Risks
Delayed monsoon impacted medical admissions in South India
Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.
medium · management_commentaryNew hospital ramp-up may pressure near-term margins
Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.
medium · analyst_questionCompetitive intensity in metro markets
Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage.
medium · analyst_questionNotable Quotes
We are on track to achieve operational break-even in quarter four FY 2024.
We are seeing that there is a higher demand that we are witnessing for both semi-private and private.
We are on track to add 2,300 beds across eight locations at a cost of INR 3,400 crore in the next three financial years.
Frequently Asked Questions
What was Apollohosp's revenue in Q2 FY24?
Apollohosp reported revenue of ₹4,847 Cr in Q2 FY24, representing a +14% change compared to the same quarter last year.
What guidance did Apollohosp management give for FY25?
Hospital EBITDA margin expansion of 200 bps: Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement. Pharmacy omni-channel revenue of INR 10,000 crore and 6%+ EBITDA margin: Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher. Apollo 24|7 operational breakeven in Q4 FY24: The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24. Addition of 2,300 beds over three years at INR 3,400 crore: Apollo plans to add 2,300 beds across eight locations over the next three financial years, with a capital outlay of INR 3,400 crore.
What are the key risks for Apollohosp in FY25?
Key risks include Delayed monsoon impacted medical admissions in South India — Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.; New hospital ramp-up may pressure near-term margins — Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.; Competitive intensity in metro markets — Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage..
Did Apollohosp meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Apollohosp Q2 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.